b
r
c
improv
understand
antigen
compon
interact
immun
system
support
comput
tool
permit
sophist
approach
modern
vaccin
design
vaccin
platform
provid
effect
tool
strateg
design
peptid
protein
antigen
modular
enhanc
immunogen
modular
vaccin
platform
overcom
issu
face
tradit
vaccin
manufactur
potenti
gener
safe
vaccin
rapidli
low
cost
review
introduc
two
promis
platform
base
viruslik
particl
liposom
discuss
methodolog
challeng
vaccin
continu
lead
defens
strategi
infecti
pathogen
tradit
vaccin
employ
wholecel
antigen
rais
immun
respons
irrefut
success
control
local
erad
diseas
poliomyel
measl
mump
rubella
influenza
hepat
b
erad
smallpox
declar
global
immun
effort
rinderpest
second
diseas
global
erad
tradit
vaccin
mean
declar
world
organ
anim
health
despit
success
live
attenu
inactiv
vaccin
possess
sever
major
drawback
live
attenu
inactiv
vaccin
requir
product
larg
volum
pathogen
form
virus
bacteria
lengthi
cultur
process
contribut
consider
lag
time
antigen
product
vaccin
deliveri
furthermor
demand
special
contain
facil
pose
consider
risk
oper
environ
due
infecti
natur
materi
despit
adequ
passag
diminish
virul
live
attenu
pathogen
capabl
revert
virul
strain
evidenc
simian
immunodefici
viru
african
hors
sick
infecti
bronchiti
viru
vaccin
genuin
threat
vaccinederiv
polio
associ
sabin
oral
polio
vaccin
hinder
immun
program
worldwid
inactiv
polio
vaccin
less
biosafeti
risk
vaccin
recipi
inactiv
polioviru
incap
replic
therebi
elimin
possibl
vaccinederiv
polio
howev
inactiv
microorgan
compromis
nativ
conform
antigen
epitop
result
reduc
immunogen
pathogen
display
high
level
antigen
owe
high
mutat
rate
eg
rna
virus
influenza
human
immunodefici
viru
exist
multipl
genotyp
serotyp
eg
rotaviru
enteroviru
group
streptococcu
present
challeng
develop
efficaci
vaccin
import
consider
vaccin
manufactur
platform
current
timescal
tradit
vaccin
manufactur
highlight
inadequaci
outbreak
influenza
middl
east
respiratori
syndrom
ebola
zika
last
decad
time
remind
improv
modern
vaccin
technolog
necessari
shorten
development
product
time
vaccin
vaccin
platform
technolog
formul
antigen
choic
predefin
platform
base
potenti
address
vaccin
manufactur
challeng
speed
safeti
efficaci
platform
base
viruslik
particl
vlp
liposom
discuss
focu
challeng
opportun
offer
vaccin
platform
technolog
tailor
platform
support
safe
simpl
manufactur
target
antigen
high
capac
potenti
rapidli
respond
emerg
diseas
vaccin
platform
technolog
consist
platform
base
carrier
fig
amend
modular
target
antigen
compon
pathogen
known
modul
independ
compon
exhibit
weak
immunogen
poor
stabil
har
immunostimulatori
properti
antigen
platform
carrier
engin
develop
enhanc
antigen
without
infecti
trait
pathogen
engin
also
allow
product
novel
vaccin
candid
obtain
tradit
method
attenu
inactiv
basic
research
determin
suitabl
modul
antigen
potenti
prerequisit
modular
approach
yet
use
gener
platform
support
streamlin
standard
vaccin
develop
potenti
reduc
cost
develop
wellexploit
platform
base
vlp
technolog
vlp
highli
order
structur
vari
degre
complex
stimul
innat
adapt
immun
respons
intrins
properti
contribut
commerci
vlpbase
vaccin
human
papillomaviru
hpv
hepat
b
e
selfadjuv
properti
vlp
due
particul
structur
optim
size
uptak
antigen
present
cell
make
attract
tool
increas
immunogen
antigen
antigen
encapsul
within
vlp
also
use
vector
drug
deliveri
well
report
platform
base
selfassembl
protein
includ
hpv
hepat
b
core
surfac
antigen
murin
polyomaviru
bacteriophag
qb
high
antigenspecif
antibodi
titer
protect
efficaci
demonstr
across
rang
peptid
epitop
protein
domain
modular
onto
vlp
platform
report
preexist
immun
vlp
protein
previou
exposur
platform
diminish
immun
respons
antigen
modul
mosquirix
tm
rt
glaxosmithklin
proteinbas
malaria
vaccin
compris
circumsporozoit
protein
hepat
b
surfac
antigen
demonstr
safeti
protect
children
infant
phase
iii
trial
recent
announc
first
pilot
studi
subsaharan
africa
liposom
anoth
favor
vaccin
platform
owe
natur
abil
induc
immun
respons
compos
aqueou
core
unior
multilamellar
phospholipid
bilay
lipidbas
vesicl
immens
adapt
paramet
relat
size
charg
lipid
adjuv
composit
antigen
present
manipul
result
versatil
liposomalbas
platform
less
welldefin
vlpbase
platform
surfac
charg
vesicl
report
import
factor
influenc
immun
respons
cation
formul
consid
effect
tool
liposom
antigen
deliveri
due
abil
bind
antigen
present
cell
electrostat
interact
form
antigen
depot
site
inject
combin
posit
charg
dimethyldioctadecylammonium
dda
immunostimul
tdb
engin
deliveri
tuberculosi
antigen
possibl
best
character
dda
tdb
also
consid
potenti
platform
chlamydia
vaccin
strategi
modular
antigen
peptid
protein
modul
onto
platform
base
key
driver
induc
protect
immun
respons
maintain
nativ
conform
structur
antigen
modul
post
modular
integr
immunostimul
platform
base
equal
import
rule
guid
vaccin
design
still
limit
although
comput
simul
tool
structurebas
vaccin
design
still
infanc
offer
altern
possibl
tradit
empir
vaccin
develop
modular
chosen
antigen
onto
vlp
achiev
electrostat
interact
chemic
conjug
genet
fusion
electrostat
interact
requir
minim
process
noncoval
interact
weak
stabil
question
varieti
linkag
chemistri
suitabl
chemic
conjug
result
perman
interact
albeit
requir
complex
manufactur
process
potenti
harsh
condit
may
alter
protein
structur
perman
regular
modul
display
afford
genet
fusion
elimin
downstream
process
yet
insert
site
modul
target
epitop
target
pathogen
bacteria
parasit
viruslik
particl
viru
liposom
fig
modular
target
epitop
onto
vlp
liposom
vaccin
platform
antigen
modul
varieti
microorgan
may
modular
onto
surfac
vlp
electrostat
interact
chemic
conjug
genet
fusion
liposom
antigen
modul
may
encapsul
aqueou
core
adsorb
lipid
bilay
conjug
coval
noncoval
vesicl
surfac
place
limit
antigen
size
may
incompat
vlp
assembl
peptid
amen
vlp
surfac
display
larg
protein
domain
although
conform
structur
compromis
ultim
affect
qualiti
immun
respons
display
larg
protein
domain
ad
benefit
present
multipl
epitop
correct
structur
may
increas
immunogen
howev
express
larg
geneticallyfus
antigen
challeng
owe
protein
fold
error
compromis
vlp
format
steric
hindranc
overcom
issu
strategi
linker
design
antigen
titrat
splitintein
conjug
tandem
core
fusion
strategi
implement
enabl
eas
larg
antigen
modular
liposom
vaccin
platform
antigen
encapsul
hydrophil
aqueou
core
intercal
lipid
bilay
surfac
attach
success
modular
antigen
kda
report
larger
describ
vlp
modular
surfac
attach
antigen
often
elicit
superior
immun
respons
comparison
encapsul
antigen
perhap
owe
intracellular
process
possibl
latter
despit
encapsul
protect
antigen
proteas
degrad
facilit
longer
circul
time
gener
effect
immun
respons
low
encapsul
effici
common
due
antigen
loss
vesicl
manufactur
process
involv
film
extrus
high
sheer
method
incub
antigen
preform
liposom
presenc
vv
ethanol
improv
encapsul
effici
may
aid
streamlin
manufactur
process
wherebi
peptid
encapsul
postproduct
unlik
vlp
technolog
modul
genet
fuse
carrier
thu
surfac
expos
antigen
reli
heavili
upon
bioconjug
technolog
coval
conjug
ie
palmitoyl
lipid
compromis
peptid
conform
potenti
result
alter
immun
respons
incorpor
appropri
linker
modul
fatti
acid
creat
spatial
separ
address
demonstr
lipotek
pti
ltd
other
use
nitrilotriacet
acid
nta
histidin
conjug
promis
yet
remain
rel
unexplor
area
liposom
technolog
nta
conjug
offer
opportun
assembl
entir
protein
domain
onto
preform
liposom
whilst
remov
costli
purif
process
novel
liposom
platform
encapsul
immunostimul
includ
diphtheria
toxoid
agonist
independ
surfac
attach
target
antigen
spatial
segreg
antigen
compon
immunostimul
expos
upon
intracellular
process
shown
enhanc
target
specif
immun
respons
tabl
summar
manufactur
technolog
modular
long
complex
vaccin
develop
process
develop
test
regulatori
requir
huge
invest
resourc
includ
time
facil
money
vaccin
manufactur
process
often
custom
conduct
dedic
facil
separ
vaccin
due
characterist
vaccin
antigen
safeti
issu
factor
pose
barrier
fast
respons
critic
control
modernday
diseas
outbreak
spread
rapidli
observ
influenza
recent
zika
platform
approach
vaccin
manufactur
ideal
streamlin
bioprocess
shorten
vaccin
product
develop
deliveri
time
market
platform
technolog
allow
standard
upstream
downstream
process
given
platform
base
remain
unchang
certainli
process
need
optim
modular
differ
antigen
modul
vaccin
platform
technolog
provid
flexibl
possibl
multiproduct
facil
prior
knowledg
experi
product
facil
setup
immens
benefici
merck
research
laboratori
use
prior
knowledg
knowhow
develop
hepat
b
vlp
vaccin
recombivax
key
decis
factor
choos
use
host
saccharomyc
cerevisia
product
hpv
vlp
vaccin
gardasil
similarli
decis
choic
adjuv
formul
hpv
vlp
made
base
recombivax
desir
lower
cost
good
thu
lead
cheaper
vaccin
market
well
discuss
debat
paper
confer
largest
vaccin
market
develop
countri
vaccin
would
signific
impact
public
health
lowincom
countri
face
vaccin
access
afford
challeng
combin
modular
singleus
technolog
modern
vaccin
manufactur
base
platform
technolog
may
potenti
lower
capit
oper
cost
result
afford
vaccin
anoth
benefit
platform
technolog
potenti
reduct
regulatori
burden
level
proof
document
requir
new
antigen
modul
gener
platform
may
lessen
regulatori
author
well
inform
regulatori
track
record
platform
base
scenario
diseas
outbreak
close
collabor
regulatori
author
may
lead
fasttrack
develop
safe
effect
vaccin
public
emerg
pathogen
benefit
vlp
liposom
platform
technolog
mani
perhap
signific
potenti
gener
multival
vaccin
vaccin
design
immun
multipl
strain
antigen
divers
pathogen
possibl
display
differ
modul
singl
platform
formul
multipl
platform
product
futur
work
expect
optim
methodolog
modul
incorpor
platform
ensur
success
modern
vaccin
